Guillain-Barré Syndrome and Visual Impairment Associated with Emerging Oropouche Virus Lineage, Brazil, 2024

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

We report a case of Guillain-Barré syndrome with visual impairment after confirmed Oropouche virus infection during the 2024 outbreak in Ceará, Brazil. Whole-genome sequencing revealed infection by a novel reassortant viral lineage (OROVBR_2025_2024), raising concern about the neurovirulence of this emerging orthobunyavirus strain.

Oropouche virus (OROV), an orthobunyavirus transmitted by mosquitoes and Culicoides paraensis midges, is emerging as a major arboviral pathogen in Latin America. Although typically associated with mild febrile illness, the current outbreak, which is linked to the novel reassortant lineage OROV BR-2015–2024 ( 1 ), has been associated with severe cases, including fatalities, vertical transmission with fetal deaths ( 2 – 4 ), and Guillain-Barré syndrome (GBS) ( 5 ). We report a case of GBS with possible bilateral optic neuritis after OROV infection during the 2024 outbreak in Ceará state, Brazil.

On August 12, 2024, a previously healthy 48-year-old woman from Capistrano in Ceará state developed acute febrile illness, characterized by high fever (39°C), chills, severe headache, and myalgia. OROV cases had been previously documented in this locality ( 2 , 6 ). On August 14, OROV infection was confirmed through quantitative reverse transcription PCR (qRT-PCR) performed by the Ceará Central Public Health Laboratory. Dengue, Zika, chikungunya, and Mayaro virus infections were excluded through both molecular and serologic testing ( Table ) ( 7 , 8 ). Fever and systemic symptoms persisted for 2 weeks and were followed by the onset of neurologic manifestations, including paresthesia in her lower limbs, which progressively developed into ascending paresis affecting both upper and lower limbs. In addition, bilateral facial weakness and profound visual loss developed. Initial treatment with corticosteroids (prednisone 40 mg/day for 7 days) was prescribed on September 15 but improvement was minimal, and the patient was referred to a tertiary hospital.

Upon admission on September 17, 2024, the patient was experiencing flaccid tetraparesis, bilateral facial paresis, and areflexia. Blood tests results were unremarkable. Analysis of cerebrospinal fluid revealed albuminocytologic dissociation, elevated protein levels, and unremarkable cell counts ( Table ), supporting a diagnosis of peripheral demyelinating neuropathy. Oligoclonal bands and IgG index testing of cerebrospinal fluid were unavailable.

Electroneuromyography showed absent sensory conduction in the left superficial fibular nerve, mildly prolonged motor latencies, and reduced motor potentials in fibular and tibial nerves. F-waves were delayed or absent, whereas the H-reflex was bilaterally absent. Electroneuromyography revealed reduced recruitment with high motor unit activity during voluntary movement, compatible with peripheral nervous system demyelination ( Appendix Tables 1–5).

Magnetic resonance imaging (MRI) of the brain showed bilateral facial nerve swelling; cervical, thoracic, and lumbar spine MRI revealed edema of lumbar nerve roots (Figure 1). Orbital MRI results were unremarkable.

Figure 1 . Imaging from study of Guillain-Barré syndrome and visual impairment associated with emerging Oropouche virus lineage, Brazil, 2024. A) T2-weighted magnetic resonance imaging of lumbar spinal cord. Arrows indicate nerve root...

Bilateral vision loss developed, accompanied by painful eye movements, compromising functional capacity as reported by the patient and family. Although the neuroophthalmologic evaluation occurred only 3 weeks after onset and during steroid treatment, the examination revealed corrected visual acuity of 20/50 in both eyes, impaired pupillary light reflexes, red dyschromatopsia, nasal optic disc edema on fundoscopy, and peripapillary retinal nerve fiber layer edema on optical coherence tomography ( Figure 1 ) without macular involvement. Visual field testing was not performed because of technical issues, and results of MRI performed at this stage were unremarkable. The evidence of subacute vision loss associated with orbital pain worsening with eye movement, reduced contrast and color vision, and pupillary deficit along with the mild optic disc swelling seen in optical coherence tomography favors the diagnosis of a possible optic neuritis ( 9 ). The temporal association of those findings with a preceding infectious episode (2–4 weeks) supports the possibility of bilateral postinfectious optic neuritis captured later in the disease evolution.

Empiric antiviral drugs and antibiotics were initiated but discontinued after excluding infectious etiologies such as Listeria and herpes. Plasmapheresis was administered in 5 sessions and was generally well tolerated, although 1 session was followed by transient dysautonomia.

The patient showed gradual but partial neurologic improvement and was discharged on October 1 with moderate gains in motor function and visual acuity. At the 90-day follow-up, the patient was able to walk with assistance, and her visual acuity remained at 20/50 in both eyes. Mild proprioceptive and sensory deficits persisted, particularly in the left foot. Deep tendon reflexes were normal except for slightly diminished Achilles reflexes.

A home visit on February 5, 2025 (6 months after symptom onset), revealed that the patient continued to experience persistent visual impairment, distal hypoesthesia, and paresis in the right lower limb, as well as difficulty standing for >15 minutes. She remained unable to resume agricultural activities or manage household routines independently and required assistance from family members for daily living. Despite partial neurologic improvement, those ongoing limitations led to functional dependence and the need for social security support. During this home visit, additional autoimmune screening tests, including tests for antinuclear antibody and aquaporin 4 and myelin oligodendrocyte glycoprotein antibodies, were performed. Results of all tests were negative ( Table ).

We performed whole-genome sequencing on patient samples using an amplicon-based protocol ( 7 ). We recovered and concatenated near-complete coding sequences of all 3 genome segments (large, medium, and small) for phylogenetic reconstruction using maximum-likelihood inference on IQ-TREE multicore version 2.1.1 ( 10 ), employing a nonredundant dataset containing previously published sequences ( 1 , 2 ). Sequence data are available on GISAID ( https://www.gisaid.org ; accession no. EPI_ISL_20332357).

Figure 2 . Maximum-likelihood tree of Oropouche virus concatenated segments from study of Guillain-Barré syndrome and visual impairment associated with emerging Oropouche virus lineage, Brazil, 2024. Black arrow indicates sequence from study patient....

The genome generated belongs to the new OROV BR/2023–2024 lineage ( 1 , 11 ). Phylogenetic analysis ( Figure 2 ) revealed a highly supported monophyletic clade (UltraFast Bootstrap 99.5, SH-aLRT 100) containing sequences from other severe cases, including a fatal vertical transmission case previously described in Ceará ( 2 ). This clade is part of a broader lineage linked to cases in Santa Catarina, Paraná, Amazonas, and Pernambuco states in Brazil, as well as to cases in Leticia, Colombia. Those sequences belong to the previously described AM-I sublineage of OROV BR-2015–2024 ( 1 , 2 , 11 ).

We report a case of GBS with visual impairment possibly caused by optic neuritis associated with the novel OROV BR-2015–2024 lineage, supported by clinical, laboratory, neuroimaging, electrophysiological, and genomic findings. Of note, the patient had been previously healthy and had no underlying conditions.

This case represents the second unusual severe event reported in this small region of Ceará, despite only a few hundred confirmed OROV cases, one of which involved a fetal death attributed to vertical transmission ( 2 , 6 ). This case highlights the neuropathogenic potential of OROV to trigger severe conditions. Although the patient received corticosteroids, intravenous immunoglobulin, and plasmapheresis, she continues to have severe neurologic impairment; whether that persistence is a result of delayed therapy or reflects a severe manifestation of OROV-associated GBS remains unclear. The phylogenetic relationship between this case and previously described cases of fetal and adult deaths ( 2 , 4 ), as well as GBS clusters reported in Cuba ( 5 ), reinforces the hypothesis that this viral lineage might possess increased pathogenicity ( 12 ).

Dr. Garcia Filho is a physician and epidemiologist at the Ceará State Health Department and a professor of medicine at the University of Fortaleza, Brazil. His primary research interests include epidemiologic surveillance and outbreak investigation.